A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).

@article{Murakami2014ASC,
  title={A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).},
  author={Haruyasu Murakami and Nobuyuki Yamamoto and Taro Shibata and Koji Takeda and Yukito Ichinose and Yuichiro Ohe and Noboru Yamamoto and Yuichiro Takeda and Shinzoh Kudoh and Shinji Atagi and Miyako Satouchi and Katsuyuki Kiura and Naoyuki Nogami and Masahiro Endo and Hirokazu Watanabe and Tomohide Tamura},
  journal={Lung cancer},
  year={2014},
  volume={84 1},
  pages={67-72}
}
OBJECTIVES We conducted an open-label, multicenter, single-arm study to confirm the efficacy and safety of amrubicin (AMR), a topoisomerase II inhibitor, for treating refractory small-cell lung cancer (SCLC). PATIENTS AND METHODS Patients with chemotherapy-refractory SCLC received 40 mg/m(2) AMR for 3 consecutive days, every 21 days. The primary endpoint was the overall response rate (ORR) and the secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Similar Papers

Loading similar papers…